Personalis (NASDAQ:PSNL) CMO Richard Chen Sells 3,998 Shares

Personalis, Inc. (NASDAQ:PSNL) CMO Richard Chen sold 3,998 shares of the company’s stock in a transaction that occurred on Friday, September 18th. The stock was sold at an average price of $16.22, for a total value of $64,847.56. Following the sale, the chief marketing officer directly owned 169,882 shares in the company, valued at $2,755,486.04. This trade represents a 2.30% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Personalis Price Performance

Shares of NASDAQ PSNL traded up $0.12 during midday trading on Tuesday, reaching $16.36. 1,369,078 shares of the stock traded hands, compared to its average volume of 2,690,633. The company’s 50 day moving average is $15.06 and its 200 day moving average is $10.89. Personalis, Inc. has a one year low of $4.95 and a one year high of $18.89. The stock has a market capitalization of $1.71 billion, a PE ratio of -15.01 and a beta of 2.31.

Personalis (NASDAQ:PSNL) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.04). The business had revenue of $22.36 million during the quarter, compared to the consensus estimate of $16.69 million. Personalis had a negative return on equity of 46.47% and a negative net margin of 153.84%. As a group, equities analysts forecast that Personalis, Inc. will post -1.07 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on PSNL. Weiss Ratings restated a “sell (d-)” rating on shares of Personalis in a research report on Friday, July 17th. Lake Street Capital lowered Personalis from a “buy” rating to a “hold” rating and set a $16.25 price target for the company. in a research report on Monday, July 20th. BTIG Research boosted their price objective on Personalis from $11.00 to $16.25 and gave the stock a “buy” rating in a research note on Monday, July 20th. Morgan Stanley upped their price objective on Personalis from $9.00 to $13.00 and gave the company an “equal weight” rating in a research report on Thursday, July 9th. Finally, Craig Hallum lowered Personalis from a “buy” rating to a “hold” rating and set a $16.25 price objective for the company. in a research note on Monday, August 24th. Four equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $14.54.

Hedge Funds Weigh In On Personalis

Several hedge funds have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd lifted its position in shares of Personalis by 76.1% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock worth $27,000 after purchasing an additional 1,479 shares during the last quarter. Quantbot Technologies LP bought a new position in shares of Personalis in the second quarter worth about $69,000. Jasper Ridge Partners L.P. purchased a new position in Personalis in the 2nd quarter worth about $193,000. AXQ Capital LP bought a new stake in Personalis during the 4th quarter valued at about $119,000. Finally, ADAR1 Capital Management LLC bought a new stake in Personalis during the 2nd quarter valued at about $201,000. Institutional investors own 61.91% of the company’s stock.

About Personalis

Personalis, Inc is a genomics company focused on precision oncology and advanced molecular testing. The company develops and commercializes genomic products designed to help identify, monitor and characterize cancer, supporting more informed treatment decisions and the development of targeted therapies.

Its offerings include tissue- and blood-based tumor profiling, liquid biopsy testing and immune profiling. Personalis’ technologies are designed to detect and track tumor-derived signals, evaluate genomic alterations and provide insights into the interaction between cancer and the immune system.